Premium
Mononuclear diorganotin(IV) complexes with arylhydroxamates: syntheses, structures and assessment of in vitro cytotoxicity
Author(s) -
Shang Xianmei,
Wu Jizhou,
Pombeiro Armando J.L.,
Li Qingshan
Publication year - 2007
Publication title -
applied organometallic chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.53
H-Index - 71
eISSN - 1099-0739
pISSN - 0268-2605
DOI - 10.1002/aoc.1312
Subject(s) - chemistry , stereochemistry , ligand (biochemistry) , cytotoxicity , in vitro , cytotoxic t cell , melting point , cisplatin , receptor , biochemistry , organic chemistry , medicine , surgery , chemotherapy
Two series of diorganotin(IV) complexes with dihalogenobenzohydroxamate ligands (substituents = 2,4‐Cl 2 , 2,4‐F 2 , 3,4‐F 2 , 2,5‐F 2 , 2,6‐F 2 ), formulated as [R 2 Sn(HL) 2 ] ( a ), and the arylhydroxamato/arylcarboxylato mixed‐ligand complexes [R 2 Sn(HL)(L′)] ( b ), were prepared and characterized by FT‐IR, 1 H, 13 C and 119 Sn NMR spectroscopies, elemental analyses and melting point measurements. X‐ray diffraction analysis was also carried out for the complex [Me 2 Sn{3,4‐F 2 C 6 H 3 C(O)NHO} 2 ], 1a . These compounds exhibit in vitro cytotoxic activities towards human leukemic promyelocites HL‐60, BGC‐823, BEL‐7402 and KB cell lines which, in some cases, are identical to, or even higher than, that of cisplatin. The type, position and number of the X substituents in the phenyl ring play a role in the cytotoxic activity, and complex 8a , with its 2,6‐difluorobenzohydroxamato ligand, is highly active against all tumor cells. A tentative structure–activity relationship is also described. Copyright © 2007 John Wiley & Sons, Ltd.